REDWOOD CITY, Calif.,
Aug. 7, 2012 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that it will release
second quarter 2012 financial results after market close on
Thursday, August 9, 2012. AcelRx
management will host an investment-community conference call at
4:30 p.m. Eastern time (1:30 p.m. Pacific time) on August 9, 2012 to discuss the financial results
and provide a corporate update.
Investors who wish to participate in the conference call may do
so by dialing (800) 860-2442 for domestic callers, or (412)
858-4600 for international callers. Those interested in listening
to the conference call live via the Internet may do so by visiting
the Investor Relations section of the company's website at
www.acelrx.com.
A webcast replay will be available on the AcelRx website for 90
days following the call by visiting the Investor Relations section
of the company's website at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, the ARX-01 Sufentanil
NanoTab PCA System, which is currently in Phase 3 clinical
development, is designed to solve the problems associated with
post-operative intravenous patient-controlled analgesia which has
been shown to cause harm to patients following surgery because of
the side effects of morphine, the invasive IV route of delivery and
the inherent potential for programming and delivery errors
associated with the complexity of infusion pumps. AcelRx has two
additional product candidates which have completed Phase 2 clinical
development: ARX-02 for the treatment of cancer breakthrough pain,
and ARX-03 for mild sedation, anxiety reduction and pain relief for
patients undergoing painful procedures in a physician's office.
AcelRx plans to initiate a Phase 2 study, pending protocol
approval, for a fourth product candidate, ARX-04, a sufentanil
formulation for the treatment of moderate-to-severe acute pain,
funded through a grant from USAMRMC. For additional
information about AcelRx's clinical programs please visit
www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to planned or
anticipated future clinical development of AcelRx Pharmaceuticals'
product candidates, and the therapeutic potential of AcelRx
Pharmaceuticals' product candidates. These forward-looking
statements are based on AcelRx Pharmaceuticals' current
expectations and inherently involve significant risks and
uncertainties. AcelRx Pharmaceuticals' actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to:
the success, cost and timing of AcelRx Pharmaceuticals' product
development activities and clinical trials; the success of its
patent prosecution strategy; its ability to protect its proprietary
technology, including the risks that pending patent applications
may not result in issued patents; its ability to obtain sufficient
financing to complete development and registration of its product
candidates in the United States
and Europe; its ability to obtain
and maintain regulatory approvals of its product candidates; the
market potential for its product candidates; and other risks
detailed in the "Risk Factors" and elsewhere in AcelRx
Pharmaceuticals' U.S. Securities and Exchange Commission filings,
including its Quarterly Report on Form 10-Q for the three months
ended March 31, 2012. AcelRx
Pharmaceuticals undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events or changes in its expectations.
SOURCE AcelRx Pharmaceuticals, Inc.